ArticleTherapeutic advances in medical oncology2019
First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis.
Article in Therapeutic advances in medical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma: a single-arm meta-analysis.Frontiers in immunology · 2026Pooled it
- First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials.Frontiers in immunology · 2025Pooled it
- Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab.Journal of gastrointestinal cancer · 2024Pooled it
- Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer.PharmacoEconomics · 2024Pooled it
- Efficacy and Safety ofFrontiers in oncology · 2021Pooled it
- Comparative study of the efficacy and safety of PSOX and SOX plus sintilimab regimens as first-line treatments for advanced gastric cancer.Anti-cancer drugs · 2026Article
- [Antitumor component-Ι inNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient-Derived Tissue Laden Tissue-Specific Bioink.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma.Frontiers in pharmacology · 2025Article
- Carpal Tunnel Syndrome as a Potential Indicator of Cardiac Amyloidosis: A Systematic Review and Meta-Analysis.Cureus · 2024Review
- Prognostic Value and Therapeutic Significance of CCL Chemokines in Gastric Cancer.Current medicinal chemistry · 2024Article
- Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy.Journal of gastrointestinal cancer · 2023Article
- Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.Journal for immunotherapy of cancer · 2023Article
- Ponciri Fructus Immatarus Sensitizes the Apoptotic Effect of Hyperthermia Treatment in AGS Gastric Cancer Cells through ROS-Dependent HSP Suppression.Biomedicines · 2023Article
- Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis.Medicine · 2022Article
- PITPNA-AS1/miR-98-5p to Mediate the Cisplatin Resistance of Gastric Cancer.Journal of oncology · 2022Article
- A Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability.Cancers · 2020Article
- EGLIF-CAR-T Cells Secreting PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer.Cancer management and research · 2020Article
- CircRNA DONSON contributes to cisplatin resistance in gastric cancer cells by regulating miR-802/BMI1 axis.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic therapy is the standard treatment against advanced gastric cancer. Fluoropyrimidine plus platinum doublet has been recommended as the preferred first-line strategy. However, there is still a lack of a comprehensive and hierarchical evidence that compares all eligible literature simultaneously.
methodsRecord retrieval was conducted in PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Embase, ASCO, and ESMO meeting library from inception to October 2018. Randomized controlled trials featuring comparisons between different first-line systemic treatments against advanced gastric cancer were eligible. Overall survival was utilized as the primary endpoint. Pairwise and network calculations were based on a random-effects model and the hierarchical ranking was numerically indicated by P-score. All procedures were conducted according to Cochrane Handbook 5.1 and PRISMA for Network Meta-analysis (Registration identifier: CRD42018084951).
resultsA total of 119 studies were eligible for our pooled analysis. Concerning general analysis, 'fluoropyrimidine plus platinum-based triplet' topped the overall survival hierarchy (HR 0.91 [0.83-0.99], P-score = 0.903,
conclusionsTaken together, fluoropyrimidine plus oxaliplatin doublet (especially capecitabine or S-1) should still be considered as the preferred first-line regimen owing to its comparable survival benefits and lower toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.